VERTEX PHARMACEUTICALS INC / MA Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount of -$99.70 million for the 9-month period ending 2021-09-30, per its 10-Q filed 2022-10-28.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate · last filed 2022-10-28
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, change in enacted tax rate, amount for the quarter ending 2021-06-30 was -$99.70M.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, change in enacted tax rate, amount for fiscal 2020 was -$37.69M.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, change in enacted tax rate, amount for fiscal 2019 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, change in enacted tax rate, amount for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, change in enacted tax rate, amount for fiscal 2017 was $575.19M, a 4381.08% increase from fiscal 2016.
| Period end | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount 3 month | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount 6 month | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount 9 month | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount 12 month |
|---|---|---|---|---|
| 2021-09-30 | -$99.70M 10-Q · filed 2022-10-28 | |||
| 2021-06-30 | -$99.70M 10-Q · filed 2022-08-05 | -$99.70M 10-Q · filed 2022-08-05 | ||
| 2020-12-31 | -$37.69M 10-K · filed 2021-02-11 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-02-11 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-11 | |||
| 2017-12-31 | $575.19M 10-K · filed 2020-02-13 | |||
| 2016-12-31 | $12.84M 10-K · filed 2019-02-13 | |||
| 2015-12-31 | -$1.22M 10-K · filed 2018-02-15 | |||
| 2014-12-31 | -$1.83M 10-K · filed 2017-02-23 | |||
| 2013-12-31 | $50.08M 10-K · filed 2016-02-16 | |||
| 2012-12-31 | $3.27M 10-K · filed 2015-02-13 | |||
| 2011-12-31 | $0.00 10-K · filed 2014-02-11 | |||
| 2010-12-31 | $0.00 10-K · filed 2013-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |